Riskpilot← Back to searchSign inGet full accessGXP PHARMAID ApS
APSActiveCVR 29615861Korsager Allé 9Engineering activities and related technical consultancy · NACE 7112Est. 20061 employeeswww.cgxp.eu
Revenue 2024
DKK 1,3M
+12% vs 2023
EBITDA margin
37.1%
-26% vs 2023
Equity ratio
60.8%
Financial strength
Net profit 2024
DKK 217K
-58% vs 2023
| Revenue | DKK 1,3M | +12% |
| EBITDA | DKK 497K | -26% |
| Net profit | DKK 217K | -58% |
| Total assets | DKK 1,8M | +7% |
| Equity | DKK 1,1M | +25% |
| Employees | 1 | — |
Legal name
GXP PHARMAID ApS
CVR number
29615861
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
23. maj 2006
Share capital
DKK 125.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at levere konsulentbistand til den farmaceutiske og bioteknologiske industri samt hermed beslægtet virksomhed efter direktionens skøn.
Address
Korsager Allé 9
Phone
+4530916335
Email
nasa@cgxp.eu
Website
www.cgxp.eu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.066 | 2.306 | 3.604 | 1.896 | 1.633 | 1.410 | 1.149 | 763 | 2.799 | 363 | 350 | 1.192 | 1.341 |
| Staff expenses | -1.271 | -1.633 | -3.038 | -2.527 | -1.504 | -1.238 | -902 | -880 | -1.559 | -990 | -735 | -517 | -844 |
| EBITDA | 795 | 673 | 566 | -631 | 129 | 172 | 247 | -118 | 1.240 | -627 | -385 | 675 | 497 |
| Depreciation & amort. | 17 | 20 | 20 | 20 | -10 | -9 | -5 | -13 | -17 | -15 | -10 | -0 | -0 |
| EBIT | 778 | 653 | 547 | -651 | 118 | 162 | 242 | -130 | 1.224 | -642 | -395 | 675 | 497 |
| Net financials | -29 | -36 | -22 | -18 | -20 | -22 | -37 | -34 | -32 | -2 | -16 | -16 | -159 |
| Profit before tax | — | 617 | 525 | -669 | 98 | 141 | 205 | -164 | 1.192 | -644 | -410 | 659 | 337 |
| Tax | 196 | 166 | 144 | -2 | 1 | -1 | -12 | 5 | 231 | -140 | -86 | 145 | 121 |
| Net profit | 553 | 451 | 380 | -667 | 97 | 142 | 217 | -169 | 960 | -504 | -325 | 513 | 217 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.497 | 2.579 | 2.555 | 1.671 | 1.539 | 1.905 | 1.864 | 1.399 | 2.984 | 1.031 | 1.246 | 1.682 | 1.802 |
| Equity | — | 1.134 | 1.114 | 447 | 544 | 687 | 904 | 735 | 1.695 | 691 | 367 | 880 | 1.096 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1.043 | 1.446 | 1.441 | 1.224 | 995 | 1.219 | 960 | 664 | 1.289 | 340 | 880 | 803 | 706 |
| Total debt | 1.043 | 1.446 | 1.441 | 1.224 | 995 | 1.219 | 960 | 664 | 1.289 | 340 | 880 | 803 | 706 |
EBITDA margin
37.1%
This company
15.8%
Market median
+135% vs market
20122024
Equity ratio
60.8%
This company
38.2%
Market median
+59% vs market
20122024
Return on equity
19.8%
This company
18.4%
Market median
+8% vs market
20122024
Net profit margin
16.1%
This company
8.1%
Market median
+99% vs market
20122024
Asset turnover
0.74×
This company
1.12×
Market median
-34% vs market
20122024
Debt / equity
0.64×
This company
0.62×
Market median
+3% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NA Management | Management | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2013 | — | — | |
| Chairman | 2013 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MAC ANDORBY ApS | Company | 100.0% | 100.0% | 2006 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MAC ANDORBY ApS
GXP PHARMAID ApS Board members of GXP PHARMAID ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nusret Asanovski | Management | 0 companies |
| Mogens Birch-Larsen | Board of Directors | 0 companies |
| Jonas Evjenios Markou | Chairman | 0 companies |